- Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs
- DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes
- The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing
- DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending
Speaking during a late 2022 interview (https://ibn.fm/cWQJX), Chris Bunka, the Chairman and CEO of Lexaria Bioscience (NASDAQ: LEXX), emphasized the varied applications of DehydraTECH(TM), and that, for example, the company intends to help people quit smoking by enabling them to satisfy their nicotine cravings in a way that will not kill them: pouches. This comes against a backdrop of worrying statistics, which show that over 480,000 people in the United States (https://ibn.fm/mE4f3) and over 8 million people globally (https://ibn.fm/lSxYa) die annually from cigarette smoking.
Lexaria also sees an opportunity to help people with hypertension, which affects about 116 million people in the US (https://ibn.fm/cqKRT) and seizure disorders, which affect 3.4 million people in the US and 65 million globally (https://ibn.fm/v87fO). “We really do believe Lexaria is going to make the world a better place,” Bunka emphasized in closing.
The company’s belief in a better tomorrow is anchored in its patented DehydraTECH technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs available in various formats, including oral ingestible, oral buccal/sublingual, and topical products. According to Lexaria, its technology “is best thought of as an additional layer that improves the effectiveness of existing or planned new products for companies that offer consumer supplements, prescription and non-prescription-based drugs, and nicotine products” (https://ibn.fm/RuNmo).
When analyzed in terms of numbers, the improvements are impressive. Having conducted both in vitro and in vivo studies, Lexaria has established that DehydraTECH increases intestinal bioabsorption of certain bioactive compounds by as much as 27 times. Furthermore, given the technology increases the quantity of each active ingredient delivered to the blood plasma and brain, it reduces the need for high doses, ultimately contributing to lower overall drug costs as lower doses can still achieve the same or even better results.
In addition, the technology works rapidly, with the DehydraTECH formulations’ effects becoming prominent in as little as 1.5 minutes post-administration. Other benefits include masked taste and smell of the active molecules, which has the intended effect of helping manufacturers create low-sugar products with fewer calories and avoid using artificial sweeteners.
Manufacturers can also register other benefits, especially considering the process is very cost-effective, according to the company. “Micro quantities of fatty acids (Generally Recognized as Safe, or GRAS, ingredients) are incorporated into drugs, consumer packaged goods, and capsule products at a fraction of a penny per serving,” the company’s website reads. “DehydraTECH technology works with process equipment readily found in most commercial kitchen/production facilities, is easily utilized under GMP certification as needed, and is highly scalable.”
The technology, which is protected by a robust suite of 28 patents granted worldwide (https://ibn.fm/fOmIF), has so far been used to enhance the capabilities of cannabidiol (“CBD”), nicotine, antivirals, and PDE5 inhibitors, to mention a few, with pharmacokinetic studies evaluating the resultant formulations showing positive results.
The recently completed HYPER-H21-4 study, for instance, which evaluated DehydraTECH-CBD as a potential treatment against hypertension, showed that the formulation resulted in statistically significant lowering of 24-hour ambulatory blood pressure as well as sustained blood pressure reduction (https://ibn.fm/64eAI). HYPER-H21-3 showed attenuated pulmonary artery systolic pressure (https://ibn.fm/CY8CH), while HYPER-H21-2 evidenced up to a 23% reduction in overnight blood pressure and reduced arterial stiffness (https://ibn.fm/k3usL). Lexaria is currently preparing the paperwork needed to file an Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”) as a precursor to commencing registered clinical trials.
Separately, in an animal study, Lexaria showed that DehydraTECH-nicotine delivered through the mucous membrane in the mouth resulted in a 10-20x reduction in time to deliver peak levels of nicotine to the bloodstream and 2-3x higher levels of nicotine in the blood (https://ibn.fm/YIJ9V). In yet another animal study comparing DehydraTECH-CBD to Epidiolex(R), the first and only FDA-approved CBD medication for the treatment of seizures, Lexaria observed that its formulation appeared to demonstrate effectiveness at lower doses and more rapidly than Epidiolex (https://ibn.fm/Zhg3G).
By targeting conditions and spaces that affect millions of lives, Lexaria is indeed working to make the world a better place, alleviating the suffering of scores of people.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX